RadioLigand Therapy with [[sup.177]Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 5
• Main Authors: Terroir, Marie, Lamesa, Chloé, Krim, Mehdi, Vija, Lavinia, Texier, Jean-Sébastien, Cassou-Mounat, Thibaut, Delord, Jean-Pierre, Vallot, Delphine, Courbon, Frédéric
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.05.2023
• Subjects: Care and treatment; Dosage and administration; Health aspects; Prostate-specific antigen; Radiopharmaceuticals; Salivary gland tumors; Testing; France

Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [[sup.177] Lu]Lu-PSMA-617 (prostate-specific membran...